logo

Esperion Therapeutics (ESPR)



Trade ESPR now with
  Date
  Headline
5/2/2018 7:41:30 AM Esperion Therapeutics Trading Halted; Expected To Resume At 8:00 AM ET
5/2/2018 7:41:11 AM Esperion Q1 Net Loss Widens To $46.1 Mln From $40.5 Mln Last Year
5/2/2018 7:31:54 AM Esperion Announces Positive Top-Line Results From Pivotal Phase 3 Long-Term Safety Study Of Bempedoic Acid
3/27/2018 7:34:08 AM Esperion Reports Positive Top-line Results From Phase 2 Clinical Study (1002-039)
3/7/2018 7:30:41 AM Esperion Announces Positive Top-Line Results From First Pivotal Phase 3 Study Of Bempedoic Acid
12/14/2017 4:39:10 PM Esperion Appoints Jeffrey Berkowitz To Board Of Directors
11/7/2017 3:36:17 PM Jefferies Is Increasing Esperion Therapeutics (ESPR) FY18 Estimate To -8.54 From -9.36
11/7/2017 3:35:58 PM Jefferies Is Increasing Esperion Therapeutics (ESPR) FY17 Estimate To -7.43 From -7.45
8/9/2017 9:30:37 PM Esperion Therapeutics Prices Public Offering Of 3.10 Mln Shares At $49.00/shr
8/8/2017 7:36:54 AM Esperion Reports Positive Top-Line Results From Phase 2 Study Of Bempedoic Acid / Ezetimibe Plus Atorvastatin